Hematology-Oncology Service, Hospital JP Garrahan, Combate de los Pozos 1881, C1245AAL, Buenos Aires, Argentina,
Paediatr Drugs. 2015 Jun;17(3):185-98. doi: 10.1007/s40272-015-0121-9.
In recent years, there have been dramatic changes in the management of intraocular retinoblastoma. Intraocular retinoblastoma is a highly curable malignancy and current treatments are aimed to preserve vision while reducing the late effects such as treatment-induced secondary malignancies. The advent of intra-arterial chemotherapy changed the treatment paradigm from systemic treatment with chemotherapy to local treatment, and new questions emerged. While intra-arterial chemotherapy achieved encouraging results, only experience from major referral centers is reported, so its indications, advantages and risks are still to be elucidated. Many factors should be considered when choosing the appropriate conservative therapy. When the disease has extended outside the eye, the chances of cure are significantly lower and treatment should be tailored by the presence of pathology risk factors such as invasion of the choroid, the optic nerve, and the sclera. Adjuvant therapy is decided upon this information. Children with overt extraocular disease are treated with higher dose neoadjuvant therapy followed by delayed enucleation and adjuvant therapy.
近年来,眼内视网膜母细胞瘤的治疗发生了重大变化。眼内视网膜母细胞瘤是一种高度可治愈的恶性肿瘤,目前的治疗方法旨在保留视力的同时减少治疗引起的继发性恶性肿瘤等晚期影响。动脉内化疗的出现改变了从全身化疗到局部治疗的治疗模式,也出现了新的问题。虽然动脉内化疗取得了令人鼓舞的结果,但目前仅报告了主要转诊中心的经验,因此其适应证、优势和风险仍有待阐明。在选择合适的保守治疗方法时,需要考虑许多因素。当疾病已经扩散到眼睛以外时,治愈的机会显著降低,治疗应根据脉络膜、视神经和巩膜浸润等病理危险因素的存在情况进行调整。辅助治疗则根据这些信息来决定。有明显眼外疾病的儿童先接受高剂量新辅助治疗,然后进行延迟眼球摘除和辅助治疗。